ReviewTransactions of the American Clinical and Climatological Association2025
BREAST CANCER: STEPS AND STUMBLES ON THE WAY TO PRECISION MEDICINE.
Review in Transactions of the American Clinical and Climatological Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treating breast cancer is both a success story and a lesson in the challenges of tailoring treatment to need. Beginning in the 1980s, multiple initiatives minimized surgical intervention and toxicity, integrated radiation therapy, and began to incorporate increasingly targeted medical therapy. Because of advances in treatment and screening, the U.S. mortality from breast cancer has dropped over 40%. However, these advances have come at a financial, physical, and social cost. It costs nearly $30 billion per year in the United States to achieve these improved outcomes in treating breast cancer, and we know that we overtreat many patients. Moreover, racial disparities in outcome persist, and many patients cannot access modern treatments. Ensuring that we give the right treatment to the right patient, and that we omit therapy when it is safe to do so, will require new strategies.
Indexed as
Identifiers
40771625PMC12323461What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.